GasGas schreef op 30 september 2014 08:03:
Goedemorgen...
02:02 EDT 30th September 2014 | BioPortfolio
Home » Corporations » Santarus, Inc. and Pharming Group NV Company Profile
Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONESTâ?¢ (RHUCIN® in non-European territories) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein. The product is also under development for follow-on indications, i.e. antibody-mediated rejection (AMR) and delayed graft function (DGF) following kidney transplantation. Pharmingâ??s advanced technologies include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website,
www.pharming.com.